BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/26/2019 11:08:19 AM | Browse: 113 | Download: 148
Publication Name World Journal of Hepatology
Manuscript ID 47665
Country of Manuscript Source United States
2019-03-22 01:58
Peer-Review Started
2019-03-25 02:24
To Make the First Decision
2019-05-23 06:00
Return for Revision
2019-06-03 03:53
2019-06-12 13:46
Second Decision
2019-06-20 06:01
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2019-06-27 17:05
Articles in Press
2019-06-27 17:05
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2019-07-26 05:58
Publish the Manuscript Online
2019-07-26 11:08
ISSN 1948-5182 (online)
Open Access This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology and Hepatology
Manuscript Type Review
Article Title Rise of sodium-glucose cotransporter 2 inhibitors in the management of nonalcoholic fatty liver disease
Manuscript Source Unsolicited Manuscript
All Author List Amr Dokmak, Mohammad Almeqdadi, Hirsh Trivedi and Sandeep Krishnan
Author(s) ORCID Number
Amr Dokmak http://orcid.org/0000-0002-0927-1486
Mohammad Almeqdadi http://orcid.org/0000-0002-5503-2371
Hirsh Trivedi http://orcid.org/0000-0002-8328-9211
Sandeep Krishnan http://orcid.org/0000-0002-5132-4342
Funding Agency and Grant Number
Corresponding author Sandeep Krishnan, MBBS, MD, Chief Physician, Doctor, Division of Gastroenterology, St. Elizabeth’s Medical Center, 736 Camrbridge st., Brighton, MA02135, United States. sandeep.krishnan@steward.org
Keywords Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Sodium-glucose cotransporter 2 inhibitors; Liver cirrhosis; Diabetes;
Core Tip Non-alcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease in the Western world. NAFLD is associated with obesity and insulin resistance. Weight loss is the cornerstone of therapy with no other proven pharmacologic therapy, Sodium-glucose co-transporter 2 (SGLT2) inhibitors may play a role in preventing and treating NAFLD. SGLT2 inhibitors reduce hepatic steatosis, steatohepatitis, and fibrosis in patients with NAFLD.
Publish Date 2019-07-26 11:08
Citation Dokmak A, Almeqdadi M, Trivedi H, Krishnan S. Rise of sodium-glucose cotransporter 2 inhibitors in the management of nonalcoholic fatty liver disease. World J Hepatol 2019; 11(7): 562-573
Url https://www.wjgnet.com/1948-5182/full/v11/i7/562.htm
DOI https://dx.doi.org/10.4254/wjh.v11.i7.562
Full Article (PDF) WJH-11-562.pdf
Full Article (Word) WJH-11-562.docx
Manuscript File 47665-Review.docx
Answering Reviewers 47665-Answering reviewers.pdf
Audio Core Tip 47665-Audio core tip.mp3
Conflict-of-Interest Disclosure Form 47665-Conflict-of-interest statement.pdf
Copyright License Agreement 47665-Copyright license agreement.pdf
Peer-review Report 47665-Peer-review(s).pdf
Scientific Misconduct Check 47665-Scientific misconduct check.pdf
Scientific Editor Work List 47665-Scientific editor work list.pdf